# A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)

> **NCT06339008** · PHASE3 · RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 450 (estimated)

## Conditions studied

- Perennial Allergic Rhinitis (PAR)

## Interventions

- **DRUG:** LY3650150
- **DRUG:** Placebo
- **DRUG:** Standard therapy for INCS

## Key facts

- **NCT ID:** NCT06339008
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-26
- **Primary completion:** 2026-09
- **Final completion:** 2028-10
- **Target enrollment:** 450 (ESTIMATED)
- **Last updated:** 2026-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06339008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06339008, "A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06339008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*